# Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

> **NCT00278330** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Blastic Phase Chronic Myelogenous Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Refractory Anemia With Excess Blasts
- Relapsing Chronic Myelogenous Leukemia
- Untreated Adult Acute Lymphoblastic Leukemia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** alvocidib
- **DRUG:** vorinostat

## Key facts

- **NCT ID:** NCT00278330
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-10
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278330, "Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT00278330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*